Revolution Medicines Inc reports results for the quarter ended December 31 - Earnings Summary

• Revolution Medicines Inc RVMD.OQ reported a quarterly adjusted loss of $1.12​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.14. The mean expectation of fifteen analysts for the quarter was for a loss of 99 cents per share. Wall Street expected results to range from $-1.15 to -92 cents per share.

• Reported revenue was zero​; analysts expected $346.15 thousand.

• Revolution Medicines Inc's reported EPS for the quarter was a loss of $1.12​.

• The company reported a quarterly loss of $194.57 million.

• Revolution Medicines Inc shares had fallen by 5.5% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Revolution Medicines Inc is $71.50

This summary was machine generated from LSEG data February 26 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)